Docoh
Loading...

CRVS Corvus Pharmaceuticals

News

From Benzinga Pro
Cantor Fitzgerald Maintains Overweight on Corvus Pharmaceuticals, Raises Price Target to $8
3 Dec 21
News, Price Target, Analyst Ratings
Cantor Fitzgerald maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Overweight and raises the price target from $5 to $8.
Jefferies Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $8
1 Dec 21
News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Roger Song initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $8.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 Dec 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Corvus Pharmaceuticals To Present Updated Mupadolimab Data At 2021 Society For Immunotherapy Of Cancer Annual Meeting
2 Nov 21
News, Events
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer
Corvus Pharmaceuticals Q3 EPS $(0.24) Up From $(0.33) YoY
1 Nov 21
Earnings, News
Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.24) per share. This is a 27.27 percent increase over losses of $(0.33) per share from the same period last year.
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
28 Oct 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours:
51 Biggest Movers From Yesterday
1 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2 earnings of $0.00 per share on sales of $3.40 million.
12 Health Care Stocks Moving In Thursday's Intraday Session
30 Sep 21
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Sep 21
Movers
Gainers
12 Health Care Stocks Moving In Tuesday's Intraday Session
28 Sep 21
Intraday Update, Markets, Movers
50 Biggest Movers From Yesterday
28 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Monday's After-Market Session
27 Sep 21
Movers
Gainers
12 Health Care Stocks Moving In Monday's Intraday Session
27 Sep 21
Intraday Update, Markets, Movers
31 Stocks Moving In Monday's Mid-Day Session
27 Sep 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover software, hardware, and support for the Simulated Mars mission.
20 Stocks Moving in Monday's Pre-Market Session
27 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-market trading.
12 Health Care Stocks Moving In Wednesday's Intraday Session
22 Sep 21
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
22 Sep 21
Pre-Market Outlook, Markets, Movers
Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program
22 Sep 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial.

Press releases

From Benzinga Pro
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
12 Nov 21
Analyst Ratings, Press Releases
Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy Corvus enrolling additional patients with these
Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
10 Nov 21
News, Press Releases
BURLINGAME, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies London Healthcare
Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2 Nov 21
News, Press Releases
BURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
1 Nov 21
Earnings, Press Releases
BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
27 Oct 21
Health Care, Press Releases
BURLINGAME, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China,
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
25 Oct 21
Press Releases
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
28 Sep 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Sept. 28, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary More than 100 companies have rushed into vaccine development against COVID-19 as the U.S. government pushes for a vaccine rollout at
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
22 Sep 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Sept. 22, 2021 /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
22 Sep 21
Health Care, Press Releases, General
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients
Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeutics, Spectrum Pharmaceuticals, or SmileDirectClub?
20 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSTM, CRVS, APRE, SPPI, and SDC.
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
20 Sep 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Sept. 20, 2021 /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more
Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biologics, Rekor Systems, SmileDirectClub, or Arcus Biosciences?
17 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, ABCL, REKR, SDC, and RCUS.
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
7 Sep 21
News, Press Releases
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will participate in two